Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Year In Review: Is Big Pharma Getting Smaller? Cost-Cutting Fails To Revive Rx Stocks

Jan 21 2008

• By The Pink Sheet

Related Content

Bristol’s Take On Restructuring: Cut $1.5 Bil. In Costs, Try BioPharma Model

Dec 10 2007

Novartis Cuts 2,500 More Jobs In Drive To Save $1.6 Billion By 2010

Dec 17 2007

Merck Q3: Zostavax Nears Part D Hurdles, Gardasil Sales On Fast Track

Oct 29 2007

Pfizer’s Manufacturing Cost-Cutting May Leave Little Capacity For Growth

Jan 29 2007

Avandia Adds Black Box For Heart Attack Risk; Actos Launches Ads

Nov 19 2007

Aranesp Bad Luck Catches Up To Amgen, Forces Pharma-Style Reorganization

Aug 20 2007

Bristol’s Pfizer, AstraZeneca Deals Could Add Up To $2 Billion To R&D Budget

Apr 30 2007

Door Open For Zelnorm Return Despite Marketing “Suspension,” Novartis Says

Apr 02 2007

Financial Analysts Roundtable: Medicare Part D, Big Pharma Diversification And The Outlook For M&amp;A

Feb 05 2007

Merck Takes Cost-Cutting Therapy, But What Will The Side Effects Be?

Dec 05 2005

Rx Stock Declines Leave Novartis, P&amp;G With More Options

Jul 15 2002

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window